论文部分内容阅读
目的探讨厄贝沙坦治疗2型糖尿病肾病对患者血清胱抑素(CysC)的影响。方法选取80例正接受有效降糖治疗的早期糖尿病肾病患者随机分成2组,对照组40例维持原治疗方案,治疗组40例在原有治疗方案基础上加用厄贝沙坦治疗24周,观察所有患者治疗前后的CysC的变化。结果治疗组患者的CysC较前明显下降(P<0.01),而对照组治疗前后CysC无明显差异。结论厄贝沙坦可显著降低早期糖尿病肾病患者的CysC。
Objective To investigate the effect of irbesartan on type 2 diabetic nephropathy on serum cystatin (CysC). Methods Eighty patients with early diabetic nephropathy undergoing effective hypoglycemic treatment were randomly divided into two groups, 40 patients in the control group maintained the original treatment, 40 patients in the treatment group were treated with irbesartan for 24 weeks on the basis of the original treatment, and observed CysC changes in all patients before and after treatment. Results The CysC of the treatment group was significantly lower than that before (P <0.01), while there was no significant difference in the CysC before and after treatment in the control group. Conclusion Irbesartan can significantly reduce CysC in patients with early diabetic nephropathy.